Radio and PodcastLive Radio & PodcastsScience & Medicine
Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis
Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis
About This Episode
Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis is an episode from FDA Drug Safety Podcasts by U.S. Food and Drug Administration, Center for Drug Evalu...
Podcast
This episode belongs to FDA Drug Safety Podcasts.
Listen Online
Use the player on this page to stream the episode online.
Episode Details
Published Jan 2, 2025, 5:00 long, audio available.
Related Episodes
Continue listening to more episodes from FDA Drug Safety Podcasts.
Questions About This Episode
What is Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis about?
Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis
Where can I listen to Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis?
You can listen to Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis online on Radio and Podcast. Open the player on this page to stream the available audio.
Which podcast is Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis from?
Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis is an episode from FDA Drug Safety Podcasts by U.S. Food and Drug Administration, Center for Drug Evaluation and Research.
How long is this episode?
This episode is 5:00 long.
When was this episode published?
This episode was published on Jan 2, 2025.
Can I save Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis for later?
Yes. Use the heart button on the episode page to add it to your favorite episodes list.
Are there related episodes from FDA Drug Safety Podcasts?
Yes. This page shows related episodes from FDA Drug Safety Podcasts when more episodes are available from the podcast feed.
Quick Answers About This Episode
Where can I listen to Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis?
You can listen to Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis on this page when the episode audio is available from the podcast feed.
Which podcast is this episode from?
Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis is from FDA Drug Safety Podcasts by U.S. Food and Drug Administration, Center for Drug Evaluation and Research.
What are the episode details?
Published Jan 2, 2025 and 5:00 long